Saving a Pharmaceutical Giant: How We Redesigned Production to Handle 385% Capacity Overload

When a leading LATAM pharmaceutical manufacturer reached out to us, they faced what seemed like an impossible situation. Their projected demand growth would push their main manufacturing site to 385% utilization on granulation and 352% on coating by 2032. With over 150 SKUs across 3 plants and an empty expansion site, they needed more than just operational tweaks—they needed a complete transformation.

What followed was one of our most comprehensive engagements: a deep-dive analysis that revealed why their current approach was doomed to fail, and how a radical redesign could not only solve their capacity crisis but position them for sustainable growth. This is the story of how we helped them avoid manufacturing collapse and emerge stronger.

The Crisis: When Mathematics Meets Reality

The numbers were stark. Under their projected demand scenario—a doubling of volume within three years to capture the country's pharmaceutical market recovery—their main main urban plant (Site A) would hit breaking point:

• Granulation: 385% utilization (needing almost 4 lines running 24/7, but having only 1)
• Coating: 352% utilization
• 17+ resources over 100% capacity

To put this in perspective: when a manufacturing resource operates at 200%+ utilization, it's not just inefficient—it's physically impossible. No amount of overtime, efficiency improvements, or operational optimization can close a gap that large. The demand simply cannot be met.

Meanwhile, their secondary plant (Site B) faced its own bottlenecks with blister packaging at 293% and granulation at 266%. Their expansion plant (Site C) sat nearly idle at less than 3% utilization—a massive underutilized asset.

Why the Obvious Solution Wouldn't Work

The client's first instinct was to modernize Site A—upgrade equipment, improve efficiency, expand capacity. We had to demonstrate why this approach was not just suboptimal, but impossible.

Location constraints: Site A sits in the capital city center, surrounded by residential and commercial development. There's literally no room to expand—the property is completely utilized.

Infrastructure limitations: The facility wasn't designed for modern pharmaceutical manufacturing. HVAC systems need complete replacement to meet current GMP classifications, electrical and water systems operate near design limits, and surfaces don't meet modern cleanability standards.

The productivity gap: Current Site A equipment operates at roughly 1.3 batches per 2-shift day (14 hours). Modern equipment achieves ~2 batches per single shift (7 hours). This isn't just about speed—it's about fundamental capability.

Most critically, the cost to rebuild Site A would equal or exceed building new capacity elsewhere, but with worse outcomes: no expansion potential, ongoing urban restrictions, and operational disruptions during reconstruction.

The Mega Plant Vision: Consolidation with Purpose

The solution wasn't just to build more capacity—it was to completely reimagine how pharmaceutical manufacturing could work. We proposed consolidating all solid dose production into their underutilized expansion site, designed from scratch as a "Mega Plant" with 5 dedicated production routes organized by batch size.

This wasn't arbitrary. The existing approach used shared resources—one granulation line serving products ranging from 50kg to 650kg batches. This created:

• Constant changeovers between vastly different batch sizes
• Setup and cleaning time dominating productive time
• Extreme scheduling complexity
• Quality risks from frequent product changes

Designing the Architecture: Five Iterations to Perfection

The route architecture didn't emerge overnight. We tested five different configurations through Monte Carlo simulation, each iteration teaching us something new:

Configuration A: Shared Resources with Modern Equipment

Maintain the pooling model but with state-of-the-art equipment. Result: Still 112% utilization—modern equipment increases speed but doesn't solve the fundamental changeover problem. Rejected.

Configuration B: 2×600kg + 2×100kg Routes

Four dedicated routes: two high-volume, two low-volume. Result: 95% utilization—technically viable but zero margin for variability or growth. Medium-volume products (100-250kg current batches) don't fit well anywhere. Rejected for lack of operational buffer.

Configuration C: 1×600kg + 2×250kg + 1×100kg Routes

Better distribution with medium-volume routes. Result: 88% utilization—improvement, but the single 600kg route couldn't handle all high-volume products without saturation. Rejected due to high-volume bottleneck.

Configuration D: 2×600kg + 1×250kg + 1×100kg Routes

Two high-volume routes solve the bottleneck. Result: 84% utilization—entering acceptable territory. However, analysis revealed that dry-mix products (no wet granulation required) were sharing routes with granulated products, suboptimal from equipment perspective. Suboptimal—opportunity identified.

Configuration E (Final): 2×600kg + 1×250kg + 1×200kg + 1×100kg Routes

The breakthrough: separate dry-mix products into their own 200kg route. Result: 78% peak utilization—optimal. This separation:

• Reduced route complexity (homogeneous processes per route)
• Eliminated granulator/dryer needs in the dry-mix route
• Reduced total annual batches to 789 (67% reduction vs. baseline)
• Kept all routes in healthy operational zones

The Lot Size Breakthrough: From 2,422 to 789 Annual Batches

The key insight wasn't just about equipment—it was about lot size reformulation. By right-sizing batches to match dedicated routes, we achieved a 67% reduction in annual batch count while maintaining inventory targets.

This wasn't just mathematical optimization. Each route was designed for specific batch size ranges:

• Two 600kg routes: High-volume stars like Product A, Product B, Product C. One specialized for uncoated tablets, the other for film-coated products (containing the single 650kg coating pan)
• One 250kg route: 26 medium-volume products achieving the sweet spot of 6-12 batches per year
• One 200kg route: 19 dry-mix products requiring no wet granulation, plus encapsulation equipment transferred from the old plant
• One 100kg route: 22 low-volume products that don't justify larger batches

Examples of the transformation:

• Product A 50mg: 135kg → 648kg batches (177 → 37 annual batches)
• Product B 500mg: 200kg → 637kg batches (92 → 29 annual batches)
• Product C 500mg: 105kg → 650kg batches (136 → 22 annual batches)

Relieving the Secondary Crisis

While designing the Mega Plant, we couldn't ignore Site B's own capacity crisis. The solution: transfer 5 high-volume product families (15 SKUs representing 56% of blister packaging load) from Site B to the Mega Plant.

This surgical transfer transformed Site B from crisis to sustainability:

• Blister packaging: 293% → 72% utilization
• Granulation: 266% → 32% utilization
• All resources dropped to healthy or warning zones

The Final Architecture: 33 Pieces of Equipment Across 5 Routes

The final specification delivered to the client's architect included:

Route Equipment Summary:

• 4 high-shear granulators (2×600kg, 1×250kg, 1×100kg)
• 4 fluid bed dryers (paired with granulators)
• 5 IBC mixers (one per route)
• 5 tablet presses (150K/hr down to 60K/hr by route)
• 4 film coating pans (specialized by batch size)
• 2 encapsulation machines (transferred from old plant)
• 8 blister packing machines (shared resource serving all routes)
• 1 dedicated a specialty product filling line (transferred equipment)

Results: Crisis Averted, Growth Enabled

The Monte Carlo simulations confirmed the transformation:

Utilization Projections (2032):

• All production routes: 50-78% utilization
• Blister packaging (controlled bottleneck): 78%
• Zero resources above 85%
• Healthy operational margins maintained through the projection period

Compare this to the default trajectory: multiple resources at 250-400% utilization, physically impossible to operate, massive lost sales, and forced subcontracting at eroded margins.

Beyond Numbers: Strategic Positioning

This wasn't just a capacity fix—it was strategic repositioning. The Mega Plant enables:

1. Market capture: Ready for the country's pharmaceutical market recovery
2. Modern efficiency: State-of-the-art equipment closing the productivity gap
3. Operational flexibility: 50-78% utilization provides buffer for demand variability
4. Reduced complexity: 67% fewer changeovers reduce quality risks and scheduling complexity
5. Future expansion: expansion site has room to grow with market recovery

The Methodology: Why Our Analysis Was Different

This wasn't back-of-envelope planning. We used Monte Carlo simulation with 100 scenarios per configuration, modeling ±30% demand variation around an already aggressive growth scenario. Every chart in our final report showed not just averages, but full distributions—minimum, 25th percentile, median, 75th percentile, and maximum utilization across all scenarios.

This approach meant that even in the most pessimistic case (demand 30% higher than the aggressive projection), the system remained operable. And in more moderate scenarios, the client would have comfortable operational margins.

Lessons for the Industry

This engagement demonstrates several critical principles for pharmaceutical capacity planning:

Dedicated routes beat shared resources when product mix is diverse. The complexity cost of changeovers often outweighs equipment utilization benefits.

Lot size optimization is often more powerful than equipment upgrades. Our 67% batch reduction was the key lever enabling the 5-route architecture.

Location constraints can make modernization impossible, not just expensive. Sometimes the right answer is to abandon and rebuild.

Data-driven iteration beats intuition. Our 5-configuration analysis revealed non-obvious insights about product placement and route specialization.

Systemic thinking is essential. Solving one plant's crisis by creating another isn't a solution—the network effect must be considered.

Next Steps for Your Manufacturing Network

If you're facing similar capacity constraints or growth challenges, the methodology we used here can be applied to your situation. Whether you need route optimization, lot size reformulation, or complete network redesign, we combine deep pharmaceutical manufacturing knowledge with advanced simulation techniques to find solutions that others miss.

The alternative to proactive capacity planning isn't gradual degradation—it's sharp operational collapse when demand exceeds physical capability. Don't wait for the 385% utilization scenario.

Ready to optimize your manufacturing network? Contact us to discuss how we can apply these techniques to your capacity challenges.